-
Abstract Number: LB 01.1
A Phase 3 study (ATLAS-PPX) to evaluate efficacy and safety of fitusiran, an siRNA therapeutic, in people with haemophilia A or B who have switched from prior factor or bypassing agent prophylaxis
-
Abstract Number: LB 01.2
Concizumab Prophylaxis in Patients With Haemophilia A or B With Inhibitors: Efficacy and Safety Results From the Primary Analysis of the Phase 3 explorer7 Trial
-
Abstract Number: LB 01.3
Relationship between transgene-produced FVIII and bleeding rates 2 years after gene transfer with valoctocogene roxaparvovec: Results from GENEr8-1
-
Abstract Number: LB 01.4
Efficacy, Safety, and Pharmacokinetics of Once-Weekly Efanesoctocog Alfa (BIVV001) Prophylaxis in Previously Treated Patients With Severe Hemophilia A: Results From the Phase 3 XTEND-1 Study
-
Abstract Number: LB 01.5
Antiplatelet effects of inhibiting coagulation factor XI in a non-human primate model of atherosclerosis
-
Abstract Number: LB 02.1
Intermediate versus low-dose low-molecular-weight heparin in pregnant and postpartum women with a history of venous thromboembolism (Highlow Study)
-
Abstract Number: LB 02.2
Hemorrhagic, Coagulopathic, and Thrombotic (HECTOR) Complications Among Critically-Ill Patients with COVID-19: An International COVID-19 Critical Care Consortium Study
-
Abstract Number: LB 02.3
Sirtuin 1 as an endogenous inhibitor of NETosis
-
Abstract Number: LB 02.4
Platelets as Versatile Effectors of Thromboinflammation in Chronic Myeloproliferative Neoplasms
-
Abstract Number: LB 02.5
Roles of FVIII in endothelial cell biology more than a coagulation factor
-
Abstract Number: OC 01.1
Base and Prime editing of DNA as a new therapeutic option for Hemophilia A
-
Abstract Number: OC 01.2
Improvements in Health-Related Quality of Life in Adults with Severe or Moderately Severe Hemophilia B After Receiving Etranacogene Dezaparvovec Gene Therapy
-
Abstract Number: OC 01.3
Elucidating the Mechanism Behind the AAV-Derived Factor VIII Assay Discrepancy
-
Abstract Number: OC 01.5
Innate and Adaptive Immune Responses to Adeno-Associated Viral Gene Therapy in the Severe Hemophilia A Dog Model
-
Abstract Number: OC 02.1
Complement Receptors Mediate Binding of Heparin-Induced Thrombocytopenia Immune Complexes to Fc Receptor Bearing Cells
-
Abstract Number: OC 02.2
Cooperation between PF4-specific antibodies in heparin-induced thrombocytopenia: a new mechanism potentially contributing to hypercoagulability and thrombosis
-
Abstract Number: OC 02.3
“Off-the-shelf” cryopreserved platelets for the detection of HIT and VITT antibodies
-
Abstract Number: OC 02.4
Persistence of Ad26.COV2.S-associated VITT and specific detection of VITT antibodies
-
Abstract Number: OC 02.5
In vivo murine studies demonstrate that neutrophil activation by anti-NAP2 antibodies contributes to vaccine-induced immune thrombocytopenia and thrombosis (VITT)
-
Abstract Number: OC 03.1
Factor XII heavy chain structure
- 1
- 2
- 3
- …
- 94
- Next Page »